Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
31 janv. 2025 11h44 HE
|
Lowey Dannenberg, P.C.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo...
NOVO NORDISK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
29 janv. 2025 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Novo...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
29 janv. 2025 11h13 HE
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
24 janv. 2025 18h02 HE
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
22 janv. 2025 08h00 HE
|
IMMvention Therapeutix, Inc.
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a...
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
18 déc. 2024 07h30 HE
|
Photys Therapeutics, Incl
Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.
Novo Nordisk A/S - share repurchase programme
16 déc. 2024 07h52 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
16 déc. 2024 01h29 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks...
Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
03 déc. 2024 06h00 HE
|
Defiance ETFs
Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...